Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Premature Birth Risk Linked to Bacteria in Cervicovaginal Space

By LabMedica International staff writers
Posted on 17 Feb 2017
Changes in microbial communities have been implicated in both health and disease and investigations into the association between the cervicovaginal (CV) microbiota and spontaneous preterm birth (SPTB) have been limited in scope and number.

Premature or preterm birth, defined as that which occurs before 37 weeks of pregnancy, is the leading cause of death worldwide among children under five years of age. In 2015, around 1 in 10 babies born in the USA were premature; however rates of premature birth in the USA fell between 2007 and 2014, partly due to reductions in the number of births to teenagers and young mothers.

A team of scientists working with the Perelman School of Medicine examined the microbiota in vaginal swabs of 1,500 pregnant women sampled at three different times during pregnancy: during weeks 16-20, weeks 20-24, and weeks 24-28. A nested case-control was performed with 80 spontaneous preterm birth (SPTB) cases and 320 term controls that were frequency matched by race to the cases. 16S rRNA gene analyses were performed to characterize the composition and structure of the CV microbiota.

The investigators performed phylotype analyses, and 127 phylotypes were detected in all samples from both cohorts. Significant associations were demonstrated between specific bacteria, in both a positive and negative manner, with SPTB. The team found 37 bacteria were significantly associated with a decreased risk of SPTB while 13 were associated with an increased risk in the primary cohort. Racial differences in these associations were evident. The validation cohort confirmed the highly significant associations between specific microbes and SPTB. Bifidobacterium species were noted to be significantly protective against SPTB at all gestational time points while BVAB2, BVAB3 and Mobiluncus were associated with a dramatic increase risk of SPTB.

The authors concluded that CV microbiota are significantly associated with SPTB. Targeting the bacteria that are associated with an increased risk of SPTB and/or enhancing the presence of the protective bacteria may serve as new therapies to reduce the rate of PTB. An abstract of the study was published on January 26, 2017, in the American Journal of Obstetrics & Gynecology.


Gold Member
Chagas Disease Test
CHAGAS Cassette
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Centromere B Assay
Centromere B Test
New
Dermatophytosis Rapid Diagnostic Kit
StrongStep Dermatophytosis Diagnostic Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.